NO323043B1 - peptid, farmasoytisk preparat som omfatter et slikt, og anvendelse av et slikt peptid til fremstilling av et farmasoytisk preparat for appetittundertrykkelse eller metthetsinduksjon. - Google Patents

peptid, farmasoytisk preparat som omfatter et slikt, og anvendelse av et slikt peptid til fremstilling av et farmasoytisk preparat for appetittundertrykkelse eller metthetsinduksjon. Download PDF

Info

Publication number
NO323043B1
NO323043B1 NO19984005A NO984005A NO323043B1 NO 323043 B1 NO323043 B1 NO 323043B1 NO 19984005 A NO19984005 A NO 19984005A NO 984005 A NO984005 A NO 984005A NO 323043 B1 NO323043 B1 NO 323043B1
Authority
NO
Norway
Prior art keywords
peptide
arg
glp
lys
ile
Prior art date
Application number
NO19984005A
Other languages
English (en)
Norwegian (no)
Other versions
NO984005L (no
NO984005D0 (no
Inventor
Lars Thim
Birgitte Schjellerup Wulff
Martin Edward Judge
Ole Dragsbaek Madsen
Jens Juul Holst
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26063575&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO323043(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO984005L publication Critical patent/NO984005L/no
Publication of NO984005D0 publication Critical patent/NO984005D0/no
Publication of NO323043B1 publication Critical patent/NO323043B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO19984005A 1996-03-01 1998-08-31 peptid, farmasoytisk preparat som omfatter et slikt, og anvendelse av et slikt peptid til fremstilling av et farmasoytisk preparat for appetittundertrykkelse eller metthetsinduksjon. NO323043B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK23196 1996-03-01
DK23096 1996-03-01
PCT/DK1997/000086 WO1997031943A1 (en) 1996-03-01 1997-02-27 Use of a pharmaceutical composition comprising an appetite-suppressing peptide

Publications (3)

Publication Number Publication Date
NO984005L NO984005L (no) 1998-08-31
NO984005D0 NO984005D0 (no) 1998-08-31
NO323043B1 true NO323043B1 (no) 2006-12-27

Family

ID=26063575

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19984005A NO323043B1 (no) 1996-03-01 1998-08-31 peptid, farmasoytisk preparat som omfatter et slikt, og anvendelse av et slikt peptid til fremstilling av et farmasoytisk preparat for appetittundertrykkelse eller metthetsinduksjon.
NO2013006C NO2013006I1 (no) 1996-03-01 2013-03-12 Teduglutide i alle dens former slik som de er beskyttet av de grunnleggende patentene

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2013006C NO2013006I1 (no) 1996-03-01 2013-03-12 Teduglutide i alle dens former slik som de er beskyttet av de grunnleggende patentene

Country Status (22)

Country Link
EP (4) EP1975177B1 (cs)
JP (1) JP4064460B2 (cs)
KR (1) KR100611130B1 (cs)
CN (1) CN1112367C (cs)
AT (3) ATE395359T1 (cs)
AU (1) AU710818B2 (cs)
BR (1) BR9707807A (cs)
CA (1) CA2246733C (cs)
CY (2) CY2619B2 (cs)
CZ (1) CZ297338B6 (cs)
DE (3) DE69740176D1 (cs)
DK (2) DK1975177T3 (cs)
ES (3) ES2187756T3 (cs)
FR (1) FR13C0009I2 (cs)
HU (1) HU229234B1 (cs)
IL (1) IL125805A0 (cs)
NO (2) NO323043B1 (cs)
PL (1) PL187095B1 (cs)
PT (1) PT1975177E (cs)
RU (1) RU2197261C2 (cs)
UA (1) UA70283C2 (cs)
WO (1) WO1997031943A1 (cs)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
ATE395359T1 (de) * 1996-03-01 2008-05-15 Novo Nordisk As Peptid zur appetitzügelung, dessen zusammensetzungen und verwendung
EP1231219B1 (en) 1996-04-12 2010-08-25 1149336 Ontario Inc. GLucagon-like peptide-2 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
DE69737916T2 (de) * 1996-11-12 2008-04-03 Novo Nordisk A/S Verwendung von GLP-1 Peptiden
US6051557A (en) * 1997-05-16 2000-04-18 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
EP1012188B1 (de) * 1997-09-12 2004-08-18 Pharis Biotec GmbH Zusammensetzung zur therapie von diabetes mellitus und fettsucht
WO1999029336A1 (en) 1997-12-05 1999-06-17 Eli Lilly And Company Glp-1 formulations
JP2002504527A (ja) * 1998-02-27 2002-02-12 ノボ ノルディスク アクティーゼルスカブ 部分的に組織化したミセル様凝集物を形成する２５％を越えるヘリックス成分を有するｇｌｐ−２誘導体
DE69942307D1 (de) * 1998-02-27 2010-06-10 Novo Nordisk As N-terminal veränderte glp-1 abkömmlinge
WO1999043705A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
WO1999047161A1 (en) * 1998-03-19 1999-09-23 Bionebraska, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
US6998387B1 (en) 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
GB2396815B (en) 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
EP1276849A4 (en) 2000-04-12 2004-06-09 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
EP1970072A1 (en) 2000-09-18 2008-09-17 Sanos Bioscience A/S Use of GLP-2 peptides for the treatment of hyperparathyroidism
DE60136958D1 (de) 2000-12-01 2009-01-22 Takeda Pharmaceutical Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
EP2990417A1 (en) 2001-12-21 2016-03-02 Human Genome Sciences, Inc. Albumin insulin fusion protein
WO2004035624A2 (en) 2002-10-14 2004-04-29 Novo Nordisk A/S Glucagon - like peptide - 2 variants
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
WO2004069314A1 (en) 2003-02-04 2004-08-19 Novo Nordisk A/S Injection device with rotatable dose setting
WO2005056036A2 (en) 2003-12-09 2005-06-23 Novo Nordisk A/S Regulation of food preference using glp-1 agonists
ES2397241T3 (es) 2004-01-21 2013-03-05 Novo Nordisk Health Care Ag Conjugación de péptidos mediante transglutaminasa
CN102816241B (zh) 2004-02-09 2015-07-22 人类基因科学公司 清蛋白融合蛋白
ES2375802T3 (es) * 2004-04-15 2012-03-06 Alkermes Pharma Ireland Limited Dispositivo de liberación sostenida a base de pol�?mero.
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
RU2262945C1 (ru) * 2004-04-29 2005-10-27 Закрытое акционерное общество "Научно-производственное предприятие "Тринита" Способ снижения массы тела в эксперименте на животных
EP2316446A1 (en) 2004-06-11 2011-05-04 Novo Nordisk A/S Counteracting drug-induced obesity using GLP-1 agonists
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
DK1877435T4 (da) 2005-05-04 2021-03-29 Zealand Pharma As Glucagon-lignende-peptid-2 (glp-2)-analoger
ATE448247T1 (de) 2005-09-22 2009-11-15 Biocompatibles Uk Ltd Fusionspolypeptide vom glp-1 (glucagon-like peptide-1) mit erhöhten peptidaseresistenz
EP1854455B1 (en) 2006-05-10 2009-10-07 Biocompatibles UK Limited Spherical microcapsules comprising GLP-1 peptides, their production and use
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
EA023886B1 (ru) 2006-11-08 2016-07-29 Зеаланд Фарма А/С Селективные аналоги глюкагонподобного пептида-2 (glp-2)
JP5351884B2 (ja) 2007-04-23 2013-11-27 インターシア セラピューティクス，インコーポレイティド インスリン分泌促進性ペプチドの懸濁製剤及び使用
US20100278843A1 (en) * 2007-08-16 2010-11-04 St. Vincent's Hospital Sydney Limited Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
ES2360782B1 (es) * 2009-07-28 2012-03-12 Grifols, S.A. Medios para cultivo de células de mamíferos que comprenden sobrenadante de etapas del fraccionamiento de Cohn y uso de los mismos.
SMT201700583T1 (it) 2009-09-28 2018-01-11 Intarcia Therapeutics Inc Instaurazione e/o terminazione rapida di erogazione di farmaci in modo sostanzialmente stazionario
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EA028929B1 (ru) 2012-05-03 2018-01-31 Зилэнд Фарма А/С Аналоги глюкагоноподобного пептида-2 (glp-2)
JP6224586B2 (ja) 2012-07-10 2017-11-01 武田薬品工業株式会社 注射用製剤
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR101576126B1 (ko) 2014-12-29 2015-12-11 부경대학교 산학협력단 αＡＬ１４ 펩타이드를 유효성분으로 함유하는 신규 비만 예방 및 치료용 약학적 조성물
KR101669140B1 (ko) 2015-04-28 2016-10-26 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
EP4278996A3 (en) 2015-06-03 2024-01-24 i2o Therapeutics, Inc. Implant placement systems
US10188135B2 (en) * 2015-11-04 2019-01-29 Stokley-Van Camp, Inc. Method for inducing satiety
KR101887576B1 (ko) * 2016-04-15 2018-08-13 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
BR112018073511A2 (pt) 2016-05-16 2019-03-26 Intarcia Therapeutics, Inc. polipeptídeos seletivos do receptor de glucagon e métodos de uso dos mesmos
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
KR102502040B1 (ko) 2016-12-09 2023-02-24 질랜드 파마 에이/에스 아실화 glp-1/glp-2 이중 효능제
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
CN118526577A (zh) 2017-06-16 2024-08-23 西兰制药公司 用于施用胰高血糖素样肽2（glp-2）类似物的剂量方案
AU2020268087A1 (en) * 2019-05-06 2021-11-25 The University Of Sydney Methods for the fractionation of proteins

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203570A (en) 1978-08-23 1980-05-20 The Western States Machine Company Power-operated loading gate for centrifugal machines incorporating an auxiliary drive device
US4546082A (en) 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
DE3382547D1 (de) 1983-01-12 1992-05-27 Chiron Corp Sekretorische expression in eukaryoten.
WO1984004330A1 (en) 1983-04-22 1984-11-08 Amgen Secretion of exogenous polypeptides from yeast
NZ207926A (en) 1983-04-25 1988-04-29 Genentech Inc Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
DK58285D0 (da) 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4632925A (en) * 1985-10-07 1986-12-30 Hoffmann-La Roche Inc. N-substituted diphenylpiperidines and antiobesity use thereof
EP0243465A1 (en) 1985-10-25 1987-11-04 Vivian L. Mackay Method of using bar1 for secreting foreign proteins
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
AU607690B2 (en) 1985-12-24 1991-03-14 Marion Laboratories, Inc. Use of synthetic sulfated saccharides to enhance wound healing
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
ATE170557T1 (de) 1987-07-24 1998-09-15 Chiron Corp Züchtung von insektenzellen mit airlift-reaktoren
US5024947A (en) 1987-07-24 1991-06-18 Cetus Corporation Serum free media for the growth on insect cells and expression of products thereby
DK463887D0 (da) 1987-09-07 1987-09-07 Novo Industri As Gaerleader
SU1697823A1 (ru) * 1988-08-01 1991-12-15 Киевский государственный институт усовершенствования врачей Способ лечени алиментарно-конституционального ожирени
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
AU4647889A (en) 1988-11-18 1990-06-12 Cetus Corporation Insect signal peptide mediated secretion of recombinant proteins
GB8910962D0 (en) 1989-05-12 1989-06-28 Natural Environment Res Novel baculovirus expression vectors and use thereof in the expression of foreign proteins in insects or insect cells
US5077214A (en) 1989-07-07 1991-12-31 The Texas A&M University System Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
US5155037A (en) 1989-08-04 1992-10-13 The Texas A&M University System Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems
US5023328A (en) 1989-08-04 1991-06-11 The Texas A&M University System Lepidopteran AKH signal sequence
DK300090D0 (da) 1990-12-19 1990-12-19 Novo Nordisk As Fremgangsmaade til fremstilling af leadersekvenser
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
ATE395359T1 (de) * 1996-03-01 2008-05-15 Novo Nordisk As Peptid zur appetitzügelung, dessen zusammensetzungen und verwendung

Also Published As

Publication number Publication date
ATE395359T1 (de) 2008-05-15
ES2306685T3 (es) 2008-11-16
ES2187756T3 (es) 2003-06-16
EP2295453A2 (en) 2011-03-16
ATE505485T1 (de) 2011-04-15
JP4064460B2 (ja) 2008-03-19
CA2246733A1 (en) 1997-09-04
CY2013008I2 (el) 2015-08-05
FR13C0009I1 (cs) 2013-03-22
DE69738695D1 (de) 2008-06-26
CN1112367C (zh) 2003-06-25
DE69717092D1 (de) 2002-12-19
JP2000505460A (ja) 2000-05-09
CY2619B2 (cs) 2013-03-13
KR19990087439A (ko) 1999-12-27
WO1997031943A1 (en) 1997-09-04
IL125805A0 (en) 1999-04-11
EP2295453A3 (en) 2011-03-30
PL328732A1 (en) 1999-02-15
ES2364705T3 (es) 2011-09-12
NO984005L (no) 1998-08-31
RU2197261C2 (ru) 2003-01-27
EP0891378B1 (en) 2002-11-13
PT1975177E (pt) 2011-07-26
CN1215405A (zh) 1999-04-28
DK0891378T3 (da) 2003-01-06
NO984005D0 (no) 1998-08-31
DE69717092T2 (de) 2003-07-24
PL187095B1 (pl) 2004-05-31
AU1871597A (en) 1997-09-16
NO2013006I2 (cs) 2013-03-12
DE69740176D1 (de) 2011-05-26
NO2013006I1 (no) 2013-04-02
EP0891378A1 (en) 1999-01-20
KR100611130B1 (ko) 2006-11-30
EP1231218B1 (en) 2008-05-14
FR13C0009I2 (fr) 2013-08-16
ATE227737T1 (de) 2002-11-15
HUP9902670A3 (en) 2000-02-28
CA2246733C (en) 2010-07-20
EP1231218A3 (en) 2002-10-30
CZ273698A3 (cs) 1998-12-16
AU710818B2 (en) 1999-09-30
EP1975177A1 (en) 2008-10-01
UA70283C2 (en) 2004-10-15
BR9707807A (pt) 1999-07-27
CZ297338B6 (cs) 2006-11-15
EP1975177B1 (en) 2011-04-13
CY2013008I1 (el) 2015-08-05
DK1975177T3 (da) 2011-07-25
EP1231218A2 (en) 2002-08-14
HU229234B1 (en) 2013-09-30

Similar Documents

Publication Publication Date Title
EP0891378B1 (en) Use of a pharmaceutical composition comprising an appetite-suppressing peptide
US5912229A (en) Use of a pharmaceutical composition comprising an appetite-suppressing peptide
US12071456B2 (en) Extended recombinant polypeptides and compositions comprising same
US10000543B2 (en) Glucose-regulating polypeptides and methods of making and using same
CN113396157A (zh) 具有降低的胰岛素受体结合亲和力的胰岛素类似物
AU694796B2 (en) Trefoil peptide dimer
KR20160007295A (ko) 인슐린 아날로그
CN115819619A (zh) 一类glp-1/y2受体双重激动剂及其应用
HK40018271A (en) Extended recombinant polypeptides and compositions comprising same
HK1238255B (en) Extended recombinant polypeptides and compositions comprising same
HK1238255A1 (en) Extended recombinant polypeptides and compositions comprising same

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: TEDUGLUTIDE; REG. NO/DATE: EU/1/12/787/001 20120926

Spc suppl protection certif: 2013006

Filing date: 20130312

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: TEDUGLUTIDE I ALLE DENS FORMER SLIK SOM DE ER BESKYTTET AV DE GRUNNLEGGENDE PATENTENE; REG. NO/DATE: EU/1/12/787/001 20120926

Spc suppl protection certif: 2013006

Filing date: 20130312

MK1K Patent expired
SPCX Expiry of an spc

Spc suppl protection certif: 2013006